Enfusion, Inc. Return on Equity (ROE)
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | (10.7%) | (2.3%) | 414.7% | (13.2%) | 10.2% | 4.4% |
Enfusion, Inc. (ENFN) Return on Equity (ROE) comparison analysis
General
LTM Return on Equity (ROE)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ENFN key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 59.0 0.0% | 79.6 34.8% | 111.7 40.4% | 150.3 34.6% | 174.5 16.1% | 201.6 15.5% |
| Cost of Goods Sold (COGS) | 17.0 | 21.4 | 31.8 | 47.1 | 57.6 | 64.9 |
% margin | 42.1 71.3% | 58.2 73.2% | 79.9 71.5% | 103.2 68.7% | 116.9 67.0% | 136.7 67.8% |
| Operating Expenses | 28.2 | 52.1 | 355.7 | 115.2 | 104.9 | 130.6 |
| Research & Development Expenses (R&D) | 4.1 | 6.3 | 153.4 | 17.2 | 19.9 | 26.7 |
| Selling, General & Administrative Expenses (SG&A) | 24.1 | 45.8 | 202.3 | 98.1 | 85.1 | 103.9 |
% margin | 13.9 23.5% | 6.1 7.6% | (275.9) (247.0%) | (12.0) (8.0%) | 11.9 6.8% | 6.2 3.1% |
| Interest Income | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 1.7 |
| Interest Expense | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 0.0 |
| Pre-tax Income | 13.1 | 4.5 | (281.7) | (12.2) | 11.5 | 7.4 |
% effective tax rate | 0.5 3.7% | 0.4 9.6% | 0.6 (0.2%) | 1.1 (8.8%) | 2.2 19.4% | 4.6 61.8% |
% margin | 12.7 21.4% | 4.1 5.1% | (282.2) (252.7%) | (13.3) (8.8%) | 6.0 3.5% | 2.8 1.4% |
| EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.10 | 0.02 |
| Diluted EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.07 | 0.01 |
% margin | 15.0 25.5% | 8.4 10.5% | (271.9) (243.4%) | (5.6) (3.7%) | 21.9 12.6% | 6.2 3.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enfusion, Inc.'s Return on Equity (ROE)?
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 4.0%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Return on Equity (ROE) for Enfusion, Inc. have been (30.2%) over the past three years, and (22.9%) over the past five years.
2) Is Enfusion, Inc.'s Return on Equity (ROE) Good?
As of today, Enfusion, Inc.'s Return on Equity (ROE) is 4.0%, which is higher than industry median of (0.0%). It indicates that Enfusion, Inc.'s Return on Equity (ROE) is Good.